M&A Deal Summary

Johnson & Johnson Acquires Actelion

On January 26, 2017, Johnson & Johnson acquired life science company Actelion for 30.0B USD

Acquisition Highlights
  • This is Johnson & Johnson’s 12th transaction in the Life Science sector.
  • This is Johnson & Johnson’s largest (disclosed) transaction.
  • This is Johnson & Johnson’s 3rd transaction in Switzerland.

M&A Deal Summary
Date 2017-01-26
Target Actelion
Sector Life Science
Buyer(s) Johnson & Johnson
Deal Type Add-on Acquisition
Deal Value 30.0B USD
Advisor(s) BofA Securities
Credit Suisse Investment Banking (Financial)
Niederer Kraft & Frey
Wachtell, Lipton, Rosen & Katz
Slaughter and May (Legal)

Target

Actelion

Allschwil, Switzerland
website
Actelion Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical need. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). The Company's portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. Actelion was formed in 1997 and has its corporate headquarters in Allschwil, Switzerland.

Search 192,723 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Johnson & Johnson

New Brunswick, New Jersey, United States

website

Category Company
Founded 1886
Sector Consumer Products
Employees132,000
Revenue 85.2B USD (2023)
DESCRIPTION
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.

Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.

DEAL STATS #
Overall 33 of 43
Sector (Life Science) 12 of 17
Type (Add-on Acquisition) 25 of 34
Country (Switzerland) 3 of 3
Year (2017) 1 of 3
Size (of disclosed) 1 of 28
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-09-16 Abbott Medical Optics

Santa Ana, California, United States

Abbott Medical Optics, Inc. is a manufacturer of ophthalmic surgery products and is known for world-class intraocular lenses used in cataract surgery. The World Health Organization estimates that approximately 20 million people are blind from age-related cataracts and that there are at least 100 million eyes with compromised visual acuity caused by cataracts. These numbers are steadily rising due to population growth and increasing life expectancy.

Buy $4.3B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-15 Johnson & Johnson - Codman Neurosurgery Business

Raynham, Massachusetts, United States

Johnson & Johnson - Codman Neurosurgery Business is a global neurosurgery and neurovascular company that offers a broad portfolio of devices for hydrocephalus management, neuro intensive care and cranial surgery, as well as aneurysm coils, vascular reconstruction devices and other technologies used in the endovascular treatment of cerebral aneurysms and stroke.

Sell $1.0B
Mergr

Product

Company

Legal